Micrornas in prostate cancer: an overview

@inproceedings{Vanacore2017MicrornasIP,
  title={Micrornas in prostate cancer: an overview},
  author={Daniela Vanacore and Mariarosaria Boccellino and Massimiliano Berretta and Carla Cavaliere and Carmine D'Aniello and Rossella Di Franco and Francesco Jacopo Romano and Micaela Montanari and Elvira La Mantia and Raffaele Piscitelli and Flavia Nocerino and Francesca Cappuccio and Giovanni Grimaldi and Alessandro Izzo and Luigi Castaldo and Maria Filomena Pepe and Maria Gabriella Malzone and Gelsomina Iovane and Gianluca Ametrano and Paola Stiuso and Lucio Quagliuolo and Daniela Barberio and Sisto Perdon{\'a} and Paolo Muto and Maurizio Montella and Piera Maiolino and Bianca Maria Veneziani and Gerardo Botti and Michele Caraglia and Gaetano Facchini},
  booktitle={Oncotarget},
  year={2017}
}
Prostate cancer is the second highest cause of cancer mortality after lung tumours. In USA it affects about 2.8 million men and the incidence increases with age in many countries. Therefore, early diagnosis is a very important step for patient clinical evaluation and for a selective and efficient therapy. The study of miRNAs' functions and molecular mechanisms has brought new knowledge in biological processes of cancer. In prostate cancer there is a deregulation of several miRNAs that may… CONTINUE READING
Highly Cited
This paper has 41 citations. REVIEW CITATIONS
Recent Discussions
This paper has been referenced on Twitter 2 times over the past 90 days. VIEW TWEETS

From This Paper

Figures, tables, and topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 12 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 115 references

Hypofractionated versus conventional radiotherapy in patients with low/intermediate-risk localized prostate cancer: review of rectal and urinary toxicity

  • R Di Franco, V Borzillo, +10 authors D Vanacore
  • WCRJ. 2016;
  • 2016

Similar Papers

Loading similar papers…